GlobeNewswire: Abattis Bioceuticals Corp. Contains the last 10 of 58 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:24:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/03/19/2196220/0/en/Abattis-and-Management-Overcome-Legal-and-Regulatory-Allegations.html?f=22&fvtc=4&fvtv=37378Abattis and Management Overcome Legal and Regulatory Allegations2021-03-19T13:00:00Z<![CDATA[After Over Two Years of Legal and Regulatory Battles, Abattis & its Management Receive Vindication]]>https://www.globenewswire.com/news-release/2019/11/08/1944342/0/en/Abattis-Provides-Update-on-Trading-Halt-and-Corporate-Developments.html?f=22&fvtc=4&fvtv=37378Abattis Provides Update on Trading Halt and Corporate Developments2019-11-08T22:00:00Z<![CDATA[VANCOUVER, British Columbia, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) announces the following updates on recent developments related to Abattis since the trading of the Company’s common shares on the Canadian Stock Exchange (the “CSE”) was halted on February 4, 2019 (the “Halt”).]]>https://www.globenewswire.com/news-release/2019/08/09/1900070/0/en/Abattis-Completes-Year-End-Audit-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=37378Abattis Completes Year End Audit and Provides Corporate Update2019-08-09T17:35:30Z<![CDATA[VANCOUVER, British Columbia, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) announces the filing of its annual financial statements for the year ended September 30, 2018 and is pleased to provide the following comprehensive update on recent developments related to Abattis since the trading of the Company’s common shares (each, a “Share”) was halted on the Canadian Securities Exchange (“CSE”) on February 4, 2019.]]>https://www.globenewswire.com/news-release/2019/05/21/1840448/0/en/Abattis-Announces-Successful-Closing-of-Pro-Natura-Acquisition.html?f=22&fvtc=4&fvtv=37378Abattis Announces Successful Closing of Pro Natura Acquisition2019-05-21T20:58:49Z<![CDATA[VANCOUVER, British Columbia, May 21, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”).]]>https://www.globenewswire.com/news-release/2019/02/28/1743917/0/en/Abattis-Provides-Update-on-Conference-Call.html?f=22&fvtc=4&fvtv=37378Abattis Provides Update on Conference Call2019-02-28T01:07:41Z<![CDATA[VANCOUVER, British Columbia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019.]]>https://www.globenewswire.com/news-release/2019/02/18/1733818/0/en/Abattis-Provides-Update-on-Trading-Halt-and-Announces-Management-Conference-Call.html?f=22&fvtc=4&fvtv=37378Abattis Provides Update on Trading Halt and Announces Management Conference Call2019-02-18T16:00:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019.]]>https://www.globenewswire.com/news-release/2019/01/17/1701275/0/en/Abattis-Removed-From-BCSC-Temporary-Order.html?f=22&fvtc=4&fvtv=37378Abattis Removed From BCSC Temporary Order2019-01-17T13:27:11Z<![CDATA[VANCOUVER, British Columbia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis.]]>https://www.globenewswire.com/news-release/2019/01/11/1690300/0/en/Abattis-Enters-Into-Definitive-Share-Exchange-Agreement-With-NutriVida.html?f=22&fvtc=4&fvtv=37378Abattis Enters Into Definitive Share Exchange Agreement With NutriVida2019-01-11T03:44:41Z<![CDATA[VANCOUVER, British Columbia, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share exchange agreement (the “Agreement”) with 1157016 B.C. Ltd., dba NutriVida, a private arm’s length company incorporated in the Province of British Columbia (“NutriVida”), pursuant to which the Company will acquire 100% of the issued and outstanding common shares of NutriVida (the “Acquisition”).]]>https://www.globenewswire.com/news-release/2018/12/21/1677639/0/en/Abattis-Provides-Marketing-and-Operational-Updates.html?f=22&fvtc=4&fvtv=37378Abattis Provides Marketing and Operational Updates2018-12-21T13:00:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce the launch of its new website and provide an operational update.]]>https://www.globenewswire.com/news-release/2018/12/11/1665099/0/en/Comfort-Launch-by-Vergence-Naturals-Exceeds-Expectations.html?f=22&fvtc=4&fvtv=37378Comfort Launch by Vergence Naturals Exceeds Expectations2018-12-11T13:00:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update on the recent soft-launch of its cannabinoid-infused nutraceutical Comfort (“Comfort”) through the Company’s wholly-owned subsidiary, Vergence Naturals (“Vergence”), on Cyber-Monday, November 26, 2018.]]>